Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Insulin Cost Policy Impact
Insulin Cost Policy Impact on Medicare Beneficiaries

By HEOR Staff Writer

June 8, 2026

The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...
Parkinson's Cognitive Measurement
Parkinson’s Cognitive Measurement and the Impact of Precision on Forecasting

By João L. Carapinha

June 8, 2026

Parkinson's Cognitive Measurement has emerged as the decisive constraint on our ability to forecast cognitive decline in Parkinson disease. A major new analysis shows that even the most advanced machine learning models deliver only chance-level accuracy when predicting individual cognitive trajec...
mifepristone safety study
Mifepristone Safety Study: Ensuring Continued Regulatory Oversight

By João L. Carapinha

June 6, 2026

The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms. S...